Childhood Cancer Research Symposium: Cutting-edge science advancing childhood cancer treatment

More than 150 leading clinicians and scientists heard from national and international experts in childhood cancer at Hudson Institute of Medical Research on Wednesday, 13 February at a highly anticipated international symposium.

The symposium was made possible through the generous support of our premium partner, the Children’s Cancer Foundation, along with the Isabella and Marcus Foundation, Robert Connor Dawes Foundation and Azure Biosystems represented by Bioneer Pacific.

The 5th annual Childhood Cancer Research Symposium builds vital links for sharing the latest frontline knowledge between research laboratories and paediatric oncology clinics to progress solutions for childhood cancer.

This year’s symposium focused on ‘bench to bedside’, translating research findings into patient care including the latest new technologies and international discoveries.

The symposium attracted some of the world’s top researchers and clinicians working in childhood cancer. Renowned international speakers came from St Jude Children’s Research Hospital (US), The Huntsman Cancer Institute (University of Utah, US), The Children’s Brain Tumor Tissue Consortium (US) and The Hopp Children’s Cancer Center Heidelberg–KiTZ (Germany).

“Significant progress in childhood cancer research and medical care happens when leading scientists and clinicians share knowledge, exchange ideas and collaborate, irrespective of geography,” said Hudson Institute’s Associate Professor Ron Firestein.

Scientific presentations at the annual symposium highlighted leading-edge discoveries, as well as advances in big data and cancer precision medicine.

How is Hudson Institute advancing childhood cancer research?

Since it was established in September 2017, through the generous funding support of the Children’s Cancer Foundation, the Hudson Monash Paediatric Precision Medicine Program has delivered significant achievements.

Cancer precision medicine is an emerging approach to disease treatment and prevention that takes into account the uniqueness of the individual. It aims to provide the right treatment to the right patient, at the right time. Current treatment options, such as chemotherapy and radiation, do not always work and can have devastating health effects. Precision medicine technologies can significantly improve medical outcomes without subjecting cancer patients to the side effects of therapies from which they may not benefit.

This international symposium would not have been possible without the generous support of our sponsors, particularly our premium partner Children’s Cancer Foundation. Also, the Isabella and Marcus Foundation, Robert Connor Dawes Foundation and Azure Biosystems represented by Bioneer Pacific.

Contact us

Hudson Institute communications
t: + 61 3 8572 2697
e: communications@hudson.org.au